Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2005-01-26
2008-11-04
Campell, Bruce (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S040500
Reexamination Certificate
active
07445897
ABSTRACT:
Provided are compositions relating to novel MDR1 polymorphisms, including nucleic acids, polypeptides, and recombinant cells, as well as methods for detection of MDR1 polymorphisms in biological samples and elucidation of the influence of MDR1 polymorphisms on MDR1 protein function. Also provided are a rat MRP1 cDNA and protein, stable cell lines expressing the rat MRP1 protein, and methods of assessing drug penetration or disposition in a cell line expressing a recombinant mammalian MRP1 or MDR1 protein, or a homolog thereof.
REFERENCES:
patent: 5837536 (1998-11-01), McDonagh et al.
patent: 6607879 (2003-08-01), Cocks et al.
patent: 6790621 (2004-09-01), Mealey et al.
patent: 2004/0265896 (2004-12-01), Mealey et al.
Hoffmeyer et al. Functional polymorphisms of the human multidrugresistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proceedings of the National Academy of Sciences of the United States of America (Washington, DC) Mar. 28, 2000, vol. 97, No. 7, p. 3473-3478.
Chen et al. Prevalence of Multidrug Resistance Related to Activation of the mdrl Gene in Human Sarcoma Mutants Derived by Single-Step Doxorubicin Selection. Cancer Research Sep. 15, 1999, vol. 54, p. 4980-4987.
Adachi et al., “Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein,”Pharm. Res. 18:1660-1668 (2001).
Adachi et al., “Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in Situ and in Vitro,”Pharm Res. 20:1163-1169 (2003).
Allen et al., “Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance,”Cancer Res. 60:5760-5766 (2000).
Allen et al., “Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C,”Mol. Cancer Ther. 1:417-425 (2002).
Allen et al., “Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein,”Cancer Res. 63:1339-1344 (2003).
Ambudkar, “Purification and reconstitution of functional human P-glycoprotein,”J. Bioenerg. Biomembr. 27:23-29 (1995). (abstract).
Andreana et al., “Abnormal expression of a 170-kilodalton P-glycoprotein encoded byMDR1gene, a metabolically active efflux pump, in CD4+and CD8+T cells from patients with human immunodeficiency virus type 1 infection,”AIDS Res. Hum. Retroviruses12:1457-1462 (1996).
Arima et al., “Contribution of P-glycoprotein to the enhancing effects of dimethyl-β-cyclodextrin on oral bioavailability of tacrolimus,”J. Pharmacol. Exp. Ther. 297:547-555 (2001).
Bakos et al., “Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain,”J. Biol. Chem. 273:32167-32175 (1998).
Balimane, “Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discovery,”Eur. J. Pharm. Biopharm. 58:99-105 (2004).
Bardelmeijer et al., “The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery,”Invest. New Drugs18:231-241 (2000). (abstract).
Bardelmeijer et al. , “Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir,”Cancer Res. 62:6158-6154 (2002).
Bodo et al., “The role of multidrug transporters in drug availability, metabolism and toxicity,”Toxicol. Lett. 140-141:133-143 (2003).
Brimer et al., “Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein,”Pharm. Res. 17:803-810 (2000). (abstract).
Brinkmann and Eichelbaum, “Polymorphisms in the ABC drug transporter gene MDR1,”Pharmacogenomics1:59-64 (2001). (abstract).
Brinkmann et al., “Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy,”Drug Discov. Today6:835-839 (2001). (abstract).
Brumme et al., “Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response,”AIDS17:201-208 (2003).
Cascorbi et al., “Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporterMDR1gene in white subjects,”Clin.Pharmacol. Ther. 69(3):169-174 (2001).
Chan et al., “The ABCs of drug transport in intestine and liver:efflux proteins limiting drug absorption and bioavailability,”Eur. J. Pharm. Sci. 21:25-51 (2004). (abstract).
Cherrington et al., “Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats,”J. Pharmacol. Exp. Ther. 300: 97-104 (2002).
Choudri et al., “Constitutive expression of various xenobiotic and endobiotic transporter mRNAs in the Choroid plexus of rats,”Drug Metabol. Dispos. 31:1337-1345 (2003).
Cole et al., “Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells,”Cancer Res. 54:5902-5910 (1994).
Dey et al., “Pharmacokinetics of erythromycin in rabbit corneas after single-dose infusion: role of P-glycoprotein as a barrier to in vivo ocular drug absorption,”J Pharmacol. Exp. Ther. 311:246-255 (2004).
Dietrich et al., “ABC of oral bioavailability: transporters as gatekeepers in the gut,”Gut. 52:1788-1795 (2003).
Donahue et al., “Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy,”Clin. Pharmacol. Ther. 73:78-86 (2003).
Dupuis et al., “Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrevcells,”HIV Med. 4:338-345 (2003).
Durr et al., “St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4,”Clin. Pharmacol. Ther. 68:598-604 (2000). (abstract).
Dyszlewski et al., “Characterization of a novel 99mTc-carbonyl complex as a functional probe of MDR1 P-glycoprotein transport activity,”Mol. Imaging1:24-35 (2002). (abstract).
Evers et al., “Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1,”FEBS Lett. 419:112-116 (1997).
Evers et al., “Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressingcMOAT(MRP2) cDNA,”J. Clin. Invest. 101:1310-1319 (1998).
Evers et al., “Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export,”Br. J. Cancer83:375-383 (2000).
Fellay et al., “Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study,”Lancet359:30-36 (2002).
Ford et al., “Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression,”J. Antimicrob. Chemother.52:354-358 (2003).
Genne et al., “Cinchonine per os: efficient circumvention of P-glycoprotein-mediated multidrug resistance,”Anticancer Drug. Des. 10:103-118 (1995). (abstract).
Ghersi-Egea and Strazielle, “Brain drug delivery, drug metabolism, and multidrug resistance at the choroid plexus,”Microsc. Res. Tech. 52:83-88 (2001). (abstract).
Gottesman and Pastan, “Biochemistry of multidrug resistance mediated by the multidrug transporter,”Annu. Rev. Biochem. 62:385-427 (1993).
Greiner et al., “The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin,”J. Clin. Invest. 104:147-153 (1999).
Hennessy, “Intracellular accumulation of nelfinavir and its relation
Ho Rodney J. Y.
Shen Danny D.
Wu Daniel
Yang Ziping
Campell Bruce
Christensen O'Connor Johnson & Kindness PLLC
Humphrey Louise
University of Washington
LandOfFree
Sequence variants of multi-drug resistance genes, MDR1 and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sequence variants of multi-drug resistance genes, MDR1 and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sequence variants of multi-drug resistance genes, MDR1 and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4038660